Can Merck’s remigromig compete with anti-VEGF treatments after BRUNELLO results?
Merck's remigromig met BRUNELLO's vision endpoint, but higher retinal complication rates complicate its potential in diabetic macular edema.
Pharma & Biotech
Pharma & Biotech
Cadonilimab delivered 84.6% complete responses in an earlier study. Can Akeso prove lasting benefit?
Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.
Pharma & Biotech
Hovilpri healed 63% of refractory HSV lesions by Day 28. Can Asahi Kasei build a $400 million franchise?
FDA approves Hovilpri for refractory HSV in immunocompromised adults after Phase 3 pritelivir beat investigator-choice therapy on lesion healing.
Pharma & Biotech
UCB is committing $2bn to a U.S. biologics campus. The bigger test is still ahead
UCB's $2 billion Georgia biologics campus advances as drug demand rises, but manufacturing readiness and production timelines remain decisive.
Pharma & Biotech
Teva wins FDA approval for Weltruza as monthly olanzapine changes schizophrenia LAI equation
Teva’s Weltruza wins FDA approval as a monthly subcutaneous olanzapine without loading doses, oral supplementation or post-injection monitoring.
Pharma & Biotech
Sling Therapeutics reports 82% sustained response with linsitinib in thyroid eye disease
Sling reports 82% sustained response among linsitinib responders after 48 weeks off therapy. See why Phase 3 ORBIT is the next critical test.
Pharma & Biotech
Ono is paying Biohaven $80m before BHV-1300 has Phase 3 data. What exactly is it buying?
Biohaven gets $80 million upfront from Ono for Asian BHV-1300 rights as a 300-patient Phase 3 Graves’ disease trial tests the IgG degrader.
Pharma & Biotech
Roche Tecentriq FDA approval expands treatment for stage III dMMR colon cancer
FDA approval moves Tecentriq into adjuvant stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death risk.
Pharma & Biotech
Illumina launches SpliceAI2 genomic AI model for rare disease variant interpretation
Illumina says SpliceAI2 found 17% more disease-relevant splice variants, but clinical use will require more than stronger AI prediction.
Pharma & Biotech
Why Vaxcyte is seeking $1bn just days after VAX-31’s pivotal vaccine readout
Vaxcyte’s VAX-31 met pivotal Phase 3 immune-response endpoints as the company prices $1 billion to fund trials and manufacturing scale-up.